Référentiel des médicaments
Zenocutuzumab
Zenocutuzumab is a medicine in the class oncology. It is used for non-small cell lung cancer.
- Classe médicamenteuse: Oncology
- Indications: non-small cell lung cancer
Dernière mise à jour Sources: US FDA label
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Oncology
- Formes courantes
- injection
- Dosages courants
- 20 mg/ml
- Noms commerciaux
- 1
- Pays et marchés
- 1
Indications
Mécanisme d'action
Bispecific antibody that binds the extracellular domains of HER2 and HER3, inhibiting HER2:HER3 dimerization and preventing NRG1 binding to HER3. It decreases cell proliferation and PI3K-AKT-mTOR signaling, and mediates antibody-dependent cellular cytotoxicity.
Posologie adulte habituelle (résumé de la notice)
NRG1 fusion-positive NSCLC, pancreatic adenocarcinoma or cholangiocarcinoma: 750 mg IV infusion over 4 hours every 2 weeks until disease progression or unacceptable toxicity
Grossesse et allaitement
- Grossesse
- Unsafe Can cause fetal harm: HER2/HER3 loss causes malformations and embryo death in animals, and HER2 antibodies have caused low amniotic fluid. Avoid; check pregnancy status and use contraception during and for 2 months after the last dose. If exposed, monitor amniotic fluid.
- Allaitement
- Unsafe No milk data; as an IgG1 antibody little is expected in milk and it is probably digested. US label: weigh benefits, allowing for the 2-month washout. LactMed: manufacturer advises no breastfeeding during treatment and for 2 months after. Do not breastfeed until 2 months after.
Effets indésirables signalés
- Diarrhea
- Musculoskeletal pain
- Fatigue
- Nausea
- Infusion-related reactions
- Dyspnea
Mises en garde encadrées
- Embryo-fetal toxicity: exposure during pregnancy can cause embryo-fetal harm. Advise patients of this risk and the need for effective contraception.
Précautions particulières
- Serious and life-threatening infusion-related reactions, hypersensitivity and anaphylaxis can occur. Give in a setting with emergency resuscitation equipment and monitor during and for at least 1 hour after the first infusion.
- Serious and life-threatening ILD/pneumonitis can occur. Monitor for new or worsening pulmonary symptoms.
- Left ventricular dysfunction can occur. Evaluate LVEF before starting and monitor at regular intervals. It has not been studied in patients with LVEF below 50% or clinically significant cardiac disease.
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Zenocutuzumab : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- How to give it
- Pharmacokinetics
- Patient counselling points
Essayez Pro+ gratuitement pendant 14 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Zenocutuzumab used for?
Zenocutuzumab is a medicine in the class oncology. It is used for Non-small cell lung cancer, Pancreatic cancer.
What side effects have been reported with Zenocutuzumab?
Diarrhea, Musculoskeletal pain, Fatigue, Nausea, Infusion-related reactions, Dyspnea. Serious warning: Embryo-fetal toxicity: exposure during pregnancy can cause embryo-fetal harm.
Can Zenocutuzumab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: HER2/HER3 loss causes malformations and embryo death in animals, and HER2 antibodies have caused low amniotic fluid. Avoid; check pregnancy status and use contraception during and for 2 months after the last dose. If exposed, monitor amniotic fluid. Breastfeeding: Unsafe. No milk data; as an IgG1 antibody little is expected in milk and it is probably digested. US label: weigh benefits, allowing for the 2-month washout. LactMed: manufacturer advises no breastfeeding during treatment and for 2 months after. Do not breastfeed until 2 months after.
What does Zenocutuzumab interact with?
MediHelp does not list a checked interaction for Zenocutuzumab yet. Always tell your pharmacist about every medicine you take.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
